3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Hematologic Neoplasms
1
Interventions
Olanzapine
4
Cyclophosphamide
4
Voriconazole
3
Tranexamic Acid
3
Standard of Care
3
nilotinib
2
letermovir
2
fludarabine phosphate
2
Zoledronic Acid
2
Whole-Body Irradiation
2
Practice Guidelines as Topic
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methods
2
Imatinib Mesylate
2
Educational Status
2
Early Intervention, Educational
2
Doxorubicin
2
Cyclosporins
2
Cyclosporine
2
venetoclax
1
trihexyltetradecylphosphonium chloride
1
thymoglobulin
1
shengxuening
1
posaconazole
1
pembrolizumab
1
olaparib
1
maribavir
1
lenvatinib
1
ferrous succinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Neoplasms
×
fedratinib
×
Clear all
NCT01437787
2025-03-05
JAKARTA
Bristol-Myers Squibb
Phase 3
Completed
289 enrolled
1 FDA